Financial Comparison: Vasamed (OTCMKTS:VSMD) & LivaNova (NASDAQ:LIVN)

LivaNova (NASDAQ:LIVNGet Free Report) and Vasamed (OTCMKTS:VSMDGet Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Institutional & Insider Ownership

97.6% of LivaNova shares are held by institutional investors. 0.3% of LivaNova shares are held by company insiders. Comparatively, 8.0% of Vasamed shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for LivaNova and Vasamed, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LivaNova 0 4 6 1 2.73
Vasamed 0 0 0 0 0.00

LivaNova presently has a consensus target price of $81.38, indicating a potential upside of 3.52%. Given LivaNova’s stronger consensus rating and higher probable upside, equities research analysts clearly believe LivaNova is more favorable than Vasamed.

Profitability

This table compares LivaNova and Vasamed’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
LivaNova 7.48% 16.48% 7.59%
Vasamed N/A N/A N/A

Earnings and Valuation

This table compares LivaNova and Vasamed”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
LivaNova $1.39 billion 3.11 -$242.47 million $1.95 40.31
Vasamed N/A N/A N/A N/A N/A

Vasamed has lower revenue, but higher earnings than LivaNova.

Summary

LivaNova beats Vasamed on 9 of the 10 factors compared between the two stocks.

About LivaNova

(Get Free Report)

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.

About Vasamed

(Get Free Report)

Vasamed Incorporated designs, licenses, manufactures, and distributes products, software, and services for assessing and managing hemodynamic health in the United States. It offers SensiLase PAD-IQ, which supports skin perfusion pressure, pulse volume recording, and ankle brachial index calculation for Doppler-obtained pressures; and Wound Imaging & SmartDraw wound measurement systems. The company also provides PAD-IQ Studycast that provides rapid transmission of diagnostic tests to vascular specialist for interpretation of results and medically indicated therapeutic intervention; and custom carrying case to secure and protect the PAD-IQ system. It serves clinicians and patients. The company was founded in 1988 and is headquartered in Eden Prairie, Minnesota.

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.